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The Cancer Molecular Analysis Project (CMAP) of the NCI is integrating diverse cancer research data to elucidate fundamen-
tal etiologic processes, enable development of novel therapeutic approaches, and facilitate the bridging of basic and clinical
science.
The dawn of the post-genome sequence era brings the promise
of a new day in cancer research, along with an unprecedented
description of our genetic constitution and enthusiasm for
industrial-scale approaches to previously vexing problems in
cancer research. A myriad of emerging technologies are giving
us insight into the transcriptome and the proteome. These are
complemented by novel comprehensive approaches to manipu-
lating biologic systems, such as chemical genetics. New imag-
ing technologies give an extraordinary view of in vivo processes
in real time. A key challenge facing biomedicine is how to maxi-
mize our efforts. These emerging technologies will fall short of
their promise if the information they produce cannot be used to
inform one another. It is not practical to catalog all the potential
combinations and permutations of interest. The potential scien-
tific insights from the synthetic examination of data are beyond
enumeration.
Not surprisingly, early results from these technologies indi-
cate that cancer is a disease of daunting complexity. Emerging
from this apparent complexity is the understanding that cancer
may actually arise from the combination of a finite number of
fundamental molecular processes. Extracting these insights
from the collections of observations generated by the modern
technologies represents an almost overwhelming task.
Translating these insights into novel therapeutic approaches
confronts additional obstacles. Feeding back observations
made in the clinical setting to refine our knowledge of these fun-
damental processes is formidable, yet critical.
The promise that molecularly targeted cancer therapy pro-
vides compels us to confront these challenges and explore the
benefits of truly integrated biomedical observation sets. To this
end, the NCI has undertaken the Cancer Molecular Analysis
Project (CMAP). Its primary goal is to facilitate the identification
and evaluation of molecular targets in cancer. It will serve as an
infrastructure through which the threads of insight obtained
from our new technological capacity to examine cancer will be
interwoven.
Designing the CMAP
The synthesis of knowledge from disparate data is a multitiered
challenge. At a practical level, the management, integration,
visualization, and interpretation of such large data collections is
a significant technical challenge. This task is further complicat-
ed at a conceptual level. First, the observations are routinely
generated on discrete data sets, making it difficult to identify
interactions between alternative types of observations. A more
insidious barrier to integration is that each type of observation is
generated by a different portion of the scientific community.
Differences in these communities present barriers to communi-
cation of important findings. These barriers slow the rate at
which important discoveries in one domain can be translated
into another domain.
One means through which CMAP is addressing these chal-
lenges is the application of information technology. To facilitate
information interpretation and integration, CMAP utilizes a
novel bioinformatics infrastructure that spans the diverse fields
of biomedical research that constitute cancer research.
Graphical presentations of information and straightforward vir-
tual analytic tools are provided. These tools draw from a state-
of-the-art information system being developed by the NCI’s
Center for Bioinformatics (NCICB, http://ncicb.nci.nih.gov). This
infrastructure is a “knowledge stack” composed of a vocabu-
lary/ontology layer, a common data element layer, and biomed-
ical object layer (http://ncicb.nci.nih.gov/core).
CMAP currently draws data from multiple resources.
Genomic information is obtained from the National Center for
Biotechnology Information (NCBI, http://ncicb.nlm.nih.gov),
University of California Santa Cruz (http://genome.ucsc.edu),
and the NCI’s Cancer Genome Anatomy Project (CGAP,
http://cgap.nci.nih.gov). Information on molecular pathways is
obtained from BioCarta (http://www.biocarta.com). Functional
classification of genes is obtained from the Gene Ontology
Consortium (GO, http://www.geneontology.org). Information on
gene expression comes from CGAP’s serial analysis of gene
expression (SAGE) data and from the NCI’s Developmental
Therapeutics Program’s (DTP, http://dcp.nci.nih.gov) cDNA
microarray evaluation of the NCI 60 cell lines (NCI60) used for
drug screening. Molecularly targeted therapeutic agent informa-
tion is obtained from the NCI’s Cancer Therapy Evaluation
Program (CTEP, http://ctep.nci.nih.gov). Preclinical efficacy of
agents on the NCI60 is obtained from DTP. Information on clini-
cal trials is obtained from CTEP and the NCI’s Office of Cancer
Communications. The CMAP data and infrastructure are pub-
licly accessible (http://cmap.nci.nih.gov).
The information presented to the community is accessed
through different high-level organizational views that help
researchers approach the fully integrated dataset within a con-
textually familiar environment. Currently, there are four entry
points to CMAP information: molecular profiles, molecular tar-
gets, targeted agents, and trials of targeted agents.These entry
points roughly approximate the steps associated with selection,
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development, and validation of a targeted therapy. The molecu-
lar profiles section presents the molecular description of
tumors. The molecular targets section organizes and presents
molecular information by functional ontologies and molecular
pathways.The agents section provides access to information on
molecularly targeted therapeutics. Finally, the trials section cat-
alogs and describes NCI-supported clinical trials utilizing mole-
cularly targeted agents.
Orthogonal to these entry points is
the ability to determine the cancer con-
text through which information is
obtained and integrated. Information
retrieval spans the continuum from all
cancers of all types to specific histologi-
cal subtypes of cancer of a given tissue
type.This variability enables two different
lines of inquiry. When queried from a his-
tologically specific perspective, it is pos-
sible to discover molecular heterogeneity
within a cancer type. Alternatively, a
query that aggregates over multiple can-
cer types facilitates the identification of
commonalties among their molecular
architectures.
In silico hypothesis generation
through CMAP
Each of the individual sections provides
opportunities to discover patterns, view
information in biological contexts, and/or
integrate across the various cancer
research disciplines. While obviously not
a replacement for actual experimenta-
tion, the infrastructure facilitates hypoth-
esis generation from integration of com-
piled crossdisciplinary data resources.
This potential is perhaps best demon-
strated by a data-mining example.
To identify potential molecular tar-
gets in glioblastoma using the CMAP
infrastructure, one can start by looking at
molecular pathways which have genes
expressed either in the brain or in
glioblastoma based on SAGE data.
Among these is the G1/S checkpoint
pathway, one commonly felt to be critical
to abnormal cell growth. Examination of
this pathway ideogram allows one to
identify genes that show significant dif-
ferences in gene expression (Figure 1A).
The ideograms show four genes (ATR,
p15, p16, CDK4, TFDP1, and TGFβ1)
whose expression is increased in
glioblastoma relative to normal brain. Interestingly, with the
exception of TGFβ1, these genes are either the same as (p15,
p16) or adjacent to (p53, RB1) genes within the pathway that
have been described in the literature to show mutations in
glioblastomas (Figure 1B). The specific expression information
for all 26 genes within the pathway can be examined (Figure 2).
TGFβ1, TFDP1, and CDK4 show highly significant overexpres-
Figure 1. Expression differences and mutation
profiles in tissue-specific pathway context
Cell cycle G1/S checkpoint pathway from
BioCarta showing (A) genes with significant (p <
0.05) overexpression (red) in glioblastoma versus
normal brain from CGAP SAGE data and (B)
genes described in the literature to show alter-
ations in glioblastoma (yellow).
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sion in tumor when compared to normal (p < 0.00001). Among
these, only CDK4 has been annotated to have an agent for
which it is a target, flavopirodiol. Flavopirodiol is observed to be
the subject of 10 relevant trials, although none are specifically
targeted at glioblastoma.
To further evaluate the efficacy of the CDK4 target and
flavopirodiol as an agent, the CMAP infrastructure can be used
to assemble additional information. First, a virtual Northern blot
can be generated that shows the expression of CDK4 in other
tissues. CDK4 does not appear to have high expression levels
in any essential organ tissues, suggesting that potential toxicity
might be low (Figure 3). Inspection of CDK4 expression in indi-
vidual SAGE libraries indicates that its composite high expres-
sion masks variability in expression between libraries (Figure
4). This variability is reflected as well in the expression patterns
of CNS cell lines that are part of the NCI 60 screening panel
(Figure 4). Examining the results of growth inhibition studies
shows a relationship between relative expression of CDK4 and
the magnitude of growth inhibition in the CNS lines (Figure 4).
Figure 2. Virtual RNA dot blot presentation of SAGE expression data of
genes in the G1/S checkpoint pathway Figure 3. Virtual northern blot of EST and SAGE expression data for CDK4
from numerous human tissue samples
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These results suggest that assays assessing expression of
CDK4 may be an important requisite component of any suc-
cessful trial.
CMAP into the future
The above example suggests that potentially useful information
can already be drawn from CMAP infrastructure. Insight is limit-
ed, though, to the information resources upon which CMAP
draws. Other NCICB efforts will broaden this base substantially.
More specifically, the NCICB has built tools to collect animal
model data being generated within NCI’s Mouse Models of
Human Cancer Consortium (MMHCC). Cancer researchers can
use this infrastructure to add their own models to the collective.
The MMHCC will coordinate the curation of the data submitted.
This will permit users to select among the degree of vetting
associated with data they choose to explore. Similar infrastruc-
ture has been developed to allow cancer researchers to submit
gene expression data. Plans are under way to introduce chemi-
cal genomics and proteomics data.
Informatics can only partially accomplish the task of data
integration. It is clear that some categories of data may not be
generated in the course of standard cancer investigation. More
critically, observations of different types must be made against
common biologic specimens in order to meaningfully explore
their integration. To bridge these gaps,
CMAP will generate new datasets. More
specifically, CMAP will generate gene
expression information using cDNA
microarrays to measure RNA levels from
tumors. On this same collection of tumor
samples, key genes will be tested for the
presence of somatic mutations and con-
stitutional genetic variation. Additional
data resources will be generated as the need for bridges is
identified.
The CMAP effort is still in its early stages. Nevertheless,
interesting information already can be gleaned. Gaps in our
knowledge as well as connections become obvious. Not unex-
pectedly, errors, omissions, and contradictions in the data
emerge when viewed in this framework. Most of these will turn
out to be experimental errors. However, these contradictions
may challenge old assumptions and suggest new experiments
that could alter existing paradigms.
It has been suggested that the primary challenge facing
cancer research is the weaving of the disparate threads of can-
cer biology. Application of information technology to integrated
data sources, such as that being undertaken by CMAP, may be
an important first step in constructing the necessary loom.
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Figure 4. Interrelationship of selected candidate
target gene expression and growth inhibition 
Relative expression of CDK4 in (A) individual
SAGE libraries for the displayed tag contributing
to the virtual dot blot composite score and (B)
individual CNS cell lines within the NCI60 screen-
ing panel. The lower panel shows the relative
growth inhibition (GI50) for the cell lines with
respect to mean growth inhibition across all
lines, with bars to the left showing less than aver-
age inhibition and bars to the right showing
greater than average inhibition. Arrows indicate
the correspondence between relative CDK4
expression and growth inhibition.
